Savara

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Savara and other ETFs, options, and stocks.

About SVRA

Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. 

CEO
Matthew Pauls
CEOMatthew Pauls
Employees
70
Employees70
Headquarters
Langhorne, Pennsylvania
HeadquartersLanghorne, Pennsylvania
Founded
1995
Founded1995
Employees
70
Employees70

SVRA Key Statistics

Market cap
1.08B
Market cap1.08B
Price-Earnings ratio
-9.42
Price-Earnings ratio-9.42
Dividend yield
Dividend yield
Average volume
1.69M
Average volume1.69M
High today
$5.50
High today$5.50
Low today
$5.16
Low today$5.16
Open price
$5.27
Open price$5.27
Volume
1.25M
Volume1.25M
52 Week high
$7.01
52 Week high$7.01
52 Week low
$1.98
52 Week low$1.98

Stock Snapshot

With a market cap of 1.08B, Savara(SVRA) trades at $5.16. The stock has a price-to-earnings ratio of -9.42.

On 2026-06-12, Savara(SVRA) stock traded between a low of $5.16 and a high of $5.50. Shares are currently priced at $5.16, which is 0.0% above the low and -6.2% below the high.

Savara(SVRA) shares are trading with a volume of 1.25M, against a daily average of 1.69M.

During the past year, Savara(SVRA) stock moved between $1.98 at its lowest and $7.01 at its peak.

During the past year, Savara(SVRA) stock moved between $1.98 at its lowest and $7.01 at its peak.

SVRA News

Simply Wall St 2d
How Investors Are Reacting To Savara Doubling Share Authorization And Reshaping Its CFO Role

Earlier this month, Savara Inc. stockholders approved an amendment to double the company’s authorized common shares from 300,000,000 to 600,000,000, while Chief...

How Investors Are Reacting To Savara Doubling Share Authorization And Reshaping Its CFO Role
TipRanks 4d
Savara Earns Buy Rating on Strengthened Leadership and High Confidence in MOLBREEVI’s Regulatory Path and Commercial Potential

In a report released today, Francois Brisebois from LifeSci Capital reiterated a Buy rating on Savara, with a price target of $10.00. Francois Brisebois has gi...

TipRanks 4d
Savara Expands Share Capital and Updates Executive Leadership

Savara ( (SVRA) ) has issued an update. On June 4, 2026, Savara’s stockholders approved an amendment to the 2024 Omnibus Incentive Plan, increasing the pool of...

Analyst ratings

100%

of 8 ratings
Buy
100%
Hold
0%
Sell
0%

More SVRA News

TipRanks 4d
Savara says CFO Dave Lowrance stepping down for health reasons

Savara (SVRA) “announced that Dave Lowrance, Chief Financial and Administrative Officer, is stepping down from his role for health-related reasons, effective Ju...

People also own

Based on the portfolios of people who own SVRA. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.